ArticleInternational journal of molecular sciences2026
Berberine Alleviates
Meiqi Zhang, Sixian Wei, Zheng Luo, Qiqi Li, Lingdong Kong, Shiqi Wu, Meiqi Jia, Yingying Wang, Yao Wang, Anlong Xu and 1 more
Abstract read
In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Meiqi ZhangSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China.
Sixian WeiSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China.
Zheng LuoSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China.
Qiqi LiSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China.
Lingdong KongSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China.
Shiqi WuSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Meiqi JiaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China.
Yingying WangSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China.
Yao WangBeijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Xin JiaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China.ORCID 0000-0001-9414-2920 Funding
Beijing Natural Science Foundation 7242239Beijing Nova Program of Science and Technology 20240484706National Natural Science Foundation of China 82530125
6 · The paper itselfAbstract
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the intestine. Although current therapies can provide symptomatic relief, they are often associated with high costs and adverse effects.
Indexed as
BerberineCitrobacter rodentiumColitisEnterobacteriaceae InfectionsPhosphate-Binding ProteinsPyroptosisReceptors, EstrogenAnimalsDisease Models, AnimalEpithelial CellsGasderminsHMGB1 ProteinIntestinal MucosaMaleMiceMice, Inbred C57BLBerberineGasderminsGsdme protein, mouseHMGB1 ProteinPhosphate-Binding ProteinsReceptors, EstrogenBerberineGSDMEinflammatory bowel diseasepyroptosis
Identifiers
PMID42589476
PMCPMC13466967
What Socratic holds
Textmetadata
Read underepoch 390